Jan Novák

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · Blood · 2020 · 725 citations · Full text

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Carol Moreno, Richard Greil, Fatih Demırkan et al. · The Lancet Oncology · 2018 · 536 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +10

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano, Jon Salmanton‐García, Francesco Marchesi et al. · Journal of Hematology & Oncology · 2021 · 312 citations · Full text

Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study

Alison A. McCormick, Sunil Reddy, Stephen J. Reinl et al. · Proceedings of the National Academy of Sciences · 2008 · 182 citations · Full text

NKT Cells Inhibit the Onset of Diabetes by Impairing the Development of Pathogenic T Cells Specific for Pancreatic β Cells

Lucie Beaudoin, Véronique Laloux, Jan Novák et al. · Immunity · 2002 · 160 citations · Full text

Autoimmune Disease, Lymphocyte Development, Diabetes +11